Cairo – Mubasher: The consolidated net profits of the Egyptian International Pharmaceutical Industries (EIPICO) jumped by 20.90% year-on-year (YoY) to EGP 173.68 million in the first quarter (Q1) of 2022 from EGP 143.54 million.

The company generated revenues of EGP 927.37 million in Q1-22, up from EGP 800.38 million in the year-ago period, according to a bourse filing on Wednesday.

As for the standalone businesses, the company's net profits rose to EGP 185.89 million in the first three months (3M) of 2022, compared to EGP 167.19 million in the corresponding period of 2021.

It is noteworthy to mention that in 2021, EIPICO reported a 7.3% increase in its consolidated net profits to EGP 522.8 million from EGP 487.4 million in 2021, including minority shareholders' rights.